198 results
Page 2 of 10
8-K
EX-99.1
hmm3drr8y3 8ced0u3vd
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
8-K
EX-99.1
bi3ed3ob5 8o
15 Nov 23
Bio-path Holdings Reports Third Quarter 2023 Financial Results
7:30am
DEFA14A
49i1tt 8girjg1
27 Oct 23
Additional proxy soliciting materials
4:35pm
8-K
EX-99.1
60x8w0jl
24 Oct 23
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
8jjo5567
15 Aug 23
Bio-path Holdings Reports Second Quarter 2023 Financial Results
7:10am
8-K
EX-10.2
26d23s 5dxdxx55jiro
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
424B4
rt1nrc11
7 Aug 23
Prospectus supplement with pricing info
7:16am
8-K
EX-99.1
bcw05r932bspqpw462dk
12 May 23
Bio-path Holdings Reports First Quarter 2023 Financial Results
7:10am